Crescent Biopharma (CBIO) CFO receives RSU and stock option awards

Q: What insider transaction did Crescent Biopharma (CBIO) report for its CFO?

The Chief Financial Officer of Crescent Biopharma, Inc. reported receiving equity compensation on December 15, 2025 , consisting of Restricted Stock Units (RSUs) and a stock option to buy Ordinary Shares.

Q: How many Crescent Biopharma (CBIO) RSUs were granted to the CFO and how do they vest?

The CFO received an award of 14,422 RSUs , each representing a right to one Ordinary Share. These RSUs vest in approximately equal three‑month installments through the four‑year anniversary of December 15, 2025 , subject to the officer continuing to work for Crescent Biopharma or its subsidiaries.

Q: What are the terms of the Crescent Biopharma (CBIO) stock option granted to the CFO?

The officer was granted a stock option to purchase 57,688 Ordinary Shares at an exercise price of $13.21 per share. The option expires on December 15, 2035 and vests as to 1/48th of the option on each monthly anniversary of December 15, 2025, contingent on continued employment or service.

Q: What conditions apply to the vesting of the CFO’s RSUs and options at Crescent Biopharma (CBIO)?

Both the 14,422 RSUs and the 57,688-share stock option vest only if the reporting person remains continuously employed by, or provides services to, Crescent Biopharma, Inc. or its subsidiaries from December 15, 2025 through each applicable vesting date.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Crescent Biopharma, Inc. reported an equity compensation grant to its Chief Financial Officer, who is an officer and reporting person of the company. On December 15, 2025, the officer received 14,422 Ordinary Shares in the form of Restricted Stock Units (RSUs), each representing the right to receive one Ordinary Share as they vest. The RSUs are scheduled to vest in approximately equal three‑month installments over four years from December 15, 2025, conditioned on continued service.

On the same date, the officer was also granted a stock option to purchase 57,688 Ordinary Shares at an exercise price of $13.21 per share, expiring on December 15, 2035. This option vests as to 1/48th of the option on each monthly anniversary of December 15, 2025, also subject to continued employment or service with Crescent Biopharma or its subsidiaries.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Scalzo Richard William

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	57,688	$0.00	--
Grant/Award	Ordinary Shares	14,422	$0.00	--
Grant/Award	Ordinary Shares	5,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 57,688 shares (Direct); Ordinary Shares — 14,422 shares (Direct)

Footnotes (1)

Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date. This Option represents a right to purchase shares of the Issuer's Ordinary Shares and vests with respect to 1/48th of the Option on each monthly anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date.

Form 4 Insider Transactions: What Each Field Means →

12/17/2025 - 04:45 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Scalzo Richard William

(Last)

(First)

(Middle)

C/O CRESCENT BIOPHARMA, INC.

300 FIFTH AVENUE

(Street)

WALTHAM

02451

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
CRESCENT BIOPHARMA, INC. [ CBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	12/15/2025		A		14,422	A	⁽¹⁾	14,422	D
Ordinary Shares	12/15/2025		A		5,000	A	⁽¹⁾	19,422	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$13.21	12/15/2025		A		57,688		⁽²⁾	12/15/2035	Ordinary Shares	57,688	$0	57,688	D

Explanation of Responses:

1. Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date.

2. This Option represents a right to purchase shares of the Issuer's Ordinary Shares and vests with respect to 1/48th of the Option on each monthly anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date.

Remarks:

	/s/ Barbara Bispham, as attorney-in-fact for Richard William Scalzo	12/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Crescent Biopharma (CBIO) report for its CFO?

The Chief Financial Officer of Crescent Biopharma, Inc. reported receiving equity compensation on December 15, 2025, consisting of Restricted Stock Units (RSUs) and a stock option to buy Ordinary Shares.

How many Crescent Biopharma (CBIO) RSUs were granted to the CFO and how do they vest?

The CFO received an award of 14,422 RSUs, each representing a right to one Ordinary Share. These RSUs vest in approximately equal three‑month installments through the four‑year anniversary of December 15, 2025, subject to the officer continuing to work for Crescent Biopharma or its subsidiaries.

What are the terms of the Crescent Biopharma (CBIO) stock option granted to the CFO?

The officer was granted a stock option to purchase 57,688 Ordinary Shares at an exercise price of $13.21 per share. The option expires on December 15, 2035 and vests as to 1/48th of the option on each monthly anniversary of December 15, 2025, contingent on continued employment or service.

What conditions apply to the vesting of the CFO’s RSUs and options at Crescent Biopharma (CBIO)?

Both the 14,422 RSUs and the 57,688-share stock option vest only if the reporting person remains continuously employed by, or provides services to, Crescent Biopharma, Inc. or its subsidiaries from December 15, 2025 through each applicable vesting date.

What is the expiration date of the Crescent Biopharma (CBIO) stock option granted to the CFO?

The stock option granted to the Chief Financial Officer to buy 57,688 Ordinary Shares at $13.21 per share has an expiration date of December 15, 2035, if not exercised earlier and subject to its vesting conditions.

How many Crescent Biopharma (CBIO) Ordinary Shares does the CFO beneficially own after these transactions?

Following the reported RSU transactions, the Chief Financial Officer beneficially owns 19,422 Ordinary Shares directly, as shown in the non‑derivative securities table.